Profile of Ipragliflozin, an Oral SGLT-2 Inhibitor for the Treatment of Type 2 Diabetes: The Evidence to Date
Wajd Alkabbani, John-Michael Gamble School of Pharmacy, Faculty of Science, University of Waterloo, Kitchener, ON, CanadaCorrespondence: John-Michael GambleSchool of Pharmacy, Faculty of Science, University of Waterloo, 10A Victoria Street S, Kitchener, ON, N2G 1C5, CanadaTel +1 519 888 4567Fax +1 5...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2021-07-01
|
| Series: | Drug Design, Development and Therapy |
| Subjects: | |
| Online Access: | https://www.dovepress.com/profile-of-ipragliflozin-an-oral-sglt-2-inhibitor-for-the-treatment-of-peer-reviewed-fulltext-article-DDDT |